Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Escalating, Multiple-dose Study in House Dust Mite Allergic Subjects to Assess the Safety of Intradermal Injection of ToleroMune HDM.

Next Previous
Trial Profile

An Escalating, Multiple-dose Study in House Dust Mite Allergic Subjects to Assess the Safety of Intradermal Injection of ToleroMune HDM.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 31 Aug 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs HDM SPIRE (Primary)
  • Indications Allergic rhinoconjunctivitis
  • Focus Adverse reactions
  • Sponsors Niox

Most Recent Events

  • 22 Feb 2013 Results presented at the 69th Annual Meeting of the American Academy of Allergy, Asthma and Immunology.
  • 18 Nov 2010 Secondary endpoint 'Immunoglobulin-E-levels' and the primary safety endpoint have been met, according to a Circassia media release.
  • 18 Nov 2010 Brief results were reported in a Circassia media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top